{"name":"Shenzhen Hornetcorn Bio-technology Company, LTD","slug":"shenzhen-hornetcorn-bio-technology-company-ltd","ticker":"","exchange":"","domain":"","description":"Shenzhen Hornetcorn Bio-technology Company, LTD is a biotechnology firm focused on developing innovative cell therapies for various diseases. The company has a pipeline of four drugs in early to mid-stage clinical trials, primarily in the areas of immunology and oncology.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"DC-CTL","genericName":"DC-CTL","slug":"dc-ctl","indication":"Relapsed or refractory B-cell acute lymphoblastic leukemia","status":"phase_2"},{"name":"Ag-D-CIK","genericName":"Ag-D-CIK","slug":"ag-d-cik","indication":"Treatment of relapsed or refractory acute myeloid leukemia","status":"phase_2"}]}],"pipeline":[{"name":"DC-CTL","genericName":"DC-CTL","slug":"dc-ctl","phase":"phase_2","mechanism":"DC-CTL is a type of immunotherapy that uses genetically modified T cells to target and kill cancer cells.","indications":["Relapsed or refractory B-cell acute lymphoblastic leukemia","Relapsed or refractory diffuse large B-cell lymphoma"],"catalyst":""},{"name":"Ag-D-CIK","genericName":"Ag-D-CIK","slug":"ag-d-cik","phase":"phase_2","mechanism":"Ag-D-CIK is a monoclonal antibody that targets CD47.","indications":["Treatment of relapsed or refractory acute myeloid leukemia"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQVEdWY19ONURpSzFuSU80eUZQWWYyMjViZ2VGZDgzUGVtSUFqRnJHaFdJT1NyQ1E1Q2Q3ZTJ1ejB5YS1FSFFkMDJaR0pBZXpWSFpkdkphOHVpUzE4MTRMMkRLWXk4LXdKZE1va0JYejRBaWFlWUNsMmNvSXYycXdlaE1sUWRlZVljV3ZhcHBJeWQ5QUNlVVow0gGcAUFVX3lxTE1IbWxwWDJSTU96UHFyU3NXYmtza3hTUVJBanVnZV83Vk9mWHBOU2Z2UnZDY1B6S0p1b1l2WnFOV3RUcXlteTdqZmFCMGVwWEgydTFrN2lIWnYxdVNtQ1B6dHVNalVhQTFrbjVEa1FJZ1ZZNWx2dTQ0QS1oU2JmcUcxQzNnbjJzYk5ac2RwNkRENjVMVVItZEl6OHJ2cg?oc=5","date":"2015-09-11","type":"trial","source":"BioInformant","summary":"Breakdown of Mesenchymal Stem Cell Clinical Trials, by Phase, Geography, Sponsors, and More - BioInformant","headline":"Breakdown of Mesenchymal Stem Cell Clinical Trials, by Phase, Geography, Sponsors, and More","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_2":2},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}